NICE recommends GSK's Strimvelis for ADA-SCID
The U.K.'s NICE issued draft guidance recommending gene therapy Strimvelis (GSK2696273) from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) to treat severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID) for whom no suitable HLA-matched related stem cell donor is available.
The Highly Specialised Technologies (HST) Evaluation Committee estimated that the highest plausible incremental cost-effectiveness ratio (ICER) was £120,506 ($160,261) per quality-adjusted life year (QALY) gained for Strimvelis compared with a hematopoietic stem cell transplant (HSCT) from an HLA-matched unrelated donor at a 3.5% discount rate from Strimvelis' price of €594,000 ($700,445) per person. The committee estimated ICERs were lower than £100,000 per QALY gained in other scenarios, including at a discount rate of 1.5% and when compared with an HSCT from a haploidentical donor...